EGYPT – Roche Diagnostics Egypt has unveiled a new initiative dubbed ‘Peptide for Life’ in partnership with the Egyptian Society of Cardiology aimed at availing better health care for patients with heart failure in the country.

The Peptide for Life initiative will focus on furnishing affordable certified laboratory testing of the gold standard biomarker in heart failure disease (Natriuretic peptide or NP) in the Egyptian medical laboratories.

Roche Diagnostics Egypt will supply the medical laboratories – participating in this initiative – with the latest devices and chemicals to empower them to provide the test in an international quality and affordable price to the patients,” the pharmaceutical company stated.

In a press release, the company announced that the new initiative will help raise physicians’ awareness about the best use of Natriuretic Peptide testing in various patient cases and its available testing sites with a goal to advance laboratory diagnosis of heart failure.

To achieve this goal, Roche Diagnostics Egypt is tying up with the Egyptian Society of Cardiology, the largest local entity and main reference for Cardiology in Egypt, to form the Egyptian Heart Failure Working Group,” the pharma giant declared.

The main objective of the Egyptian Heart Failure Working Group is to enhance cardiologists’ understanding of the best practices for the optimal use of NP’s testing in the diagnosis, prognosis, and constant monitoring of patients in order to provide better care to those with heart failure problems.

The Group comes at a time when the role of clinical lab testing has been staggering over the past decades with over 66% of clinical decisions being impacted by lab testing results. Diagnostics allows laboratories to be the reliable partners that healthcare professionals need.

Subsequently, Roche Diagnostics Egypt is keen to bring the latest technology and encourage best practices that can heavily impact patients’ lives and push for better services for the healthcare sector across the country.

Dr. Magdy Abdel Hamid, Head of Cardiology Department at Cairo University and the President of the Egyptian Heart Failure Working Group said: “A timely and accurate diagnosis is crucial in paving the way for an early initiation of key lifesaving therapies.”

He pointed out that Natriuretic Peptide testing is highly indispensable for an accurate diagnosis of Acute Heart Failure (AHF) while noting that NP testing in emergency departments is still negligible, especially in low and middle-income countries

We need to channel out the impediments standing against guidelines implementation, alongside identifying actions that guarantee availing NB testing in the emergency departments for patients with acute dyspnea.” Dr. Hamid added.

Liliane Kanaan, General Manager of Roche Diagnostics Egypt, highlighted that the pharma giant is leveraging on multiple initiatives to boost ongoing efforts aimed at advancing guidelines of healthcare services and meeting the medical sector’s needs.

This is surely achieved through Roche’s developed innovative solutions in cooperation with our partners for reinforcing healthcare quality in public and private sectors and meeting patient needs everywhere,” she noted.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.